Bangavax

Bangavax
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Other namesBancovid
Routes of
administration
Intramuscular
ATC code
  • None

Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.[1][2][3][4][5][6] The vaccine was initially called Bancovid.[7] On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial.[8][9]

  1. ^ "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Archived from the original on 30 April 2021. Retrieved 28 April 2021.
  2. ^ "'Bangavax' to get approval within a week". The Daily Observer. 25 April 2021. Retrieved 28 April 2021.
  3. ^ "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
  4. ^ "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Archived from the original on 29 April 2021. Retrieved 28 April 2021.
  5. ^ Sumon S (8 January 2021). "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. Archived from the original on 9 January 2021. Retrieved 28 April 2021.
  6. ^ Baray JC, Khan MM, Mahmud A, Islam MJ, Myti S, Ali MR, et al. (January 2020). "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. doi:10.1101/2020.09.29.319061. S2CID 222127616.
  7. ^ "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. Dhaka. 6 January 2021. Retrieved 28 April 2021.
  8. ^ "Bangavax gets BMRC approval to start human trials". Dhaka Tribune. 23 November 2021. Retrieved 23 November 2021.
  9. ^ "Bangavax gets ethical permission for human trial". The Daily Star. 23 November 2021. Retrieved 23 November 2021.